Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
Status:
Completed
Trial end date:
2016-02-28
Target enrollment:
Participant gender:
Summary
This study is a regulatory post-marketing surveillance in Japan, and it is a local
prospective and observational study of patients who have been administered with Nexavar for
unresectable or advanced renal cell carcinoma (RCC). The objective of this study is to assess
safety and effectiveness of Nexavar under real-life practice conditions. This study is an all
case investigation of which the enrollment period is 15 months, and all patients who received
Nexavar will be recruited and followed one year since starting Nexavar administration.